Vericel (VCEL) concentration risks

The company's concentration profile centers on two high-share supply dependencies that together define the manufacturing risk surface for its cell therapy and wound care products. Matricel GmbH supplies the ACI-Maix membranes exclusively to the company under a supply agreement, a high-share dependency in character: there is no disclosed alternate supplier for this scaffold component, which is a critical input to the company's cartilage repair product. Separately, the company holds exclusive license and supply agreements with MediWound, which conducts the manufacturing process for NexoBrid, another high-share sole-source dependency with no disclosed redundant supply arrangement. Both dependencies are exclusively dependency in character rather than structural — they reflect choices to rely on single specialized manufacturers rather than a durable feature of the end-market — meaning they are, in principle, addressable through supply-chain investment, though qualifying alternative manufacturers for biological and cell therapy products is a time-consuming, regulatory-intensive process. The two sole-source relationships are independent of each other, involving different products and different manufacturers, but the combined effect is that a disruption at either Matricel or MediWound would affect a different part of the product portfolio. No customer, geographic, or product revenue concentration is separately disclosed. On balance, the profile is dominated by manufacturing dependency risk: sole-source supply arrangements for two key products represent the most direct risk to commercial continuity.

For the engine’s reasoning on VCEL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.